HZNP - Horizon Pharma Public Limited Company

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
15.04
-0.17 (-1.12%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close15.21
Open15.22
Bid14.54 x 100
Ask15.89 x 100
Day's Range14.85 - 15.25
52 Week Range9.45 - 17.69
Volume1,261,899
Avg. Volume2,105,727
Market Cap2.465B
Beta0.72
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters12 days ago

    U.S. pharma executives expect deals to pick up after tax overhaul

    The Trump administration's tax overhaul should accelerate major acquisitions by drugmakers in 2018 after a slow year for deals in 2017, according to senior executives from some of the largest pharmaceutical manufacturers. The $1.5-trillion bill, which U.S. President Donald Trump signed into law in December, lowers the income tax rate for U.S. companies to 21 percent from 35 percent, encourages them to repatriate cash, and modifies numerous deductions. Brent Saunders, chief executive officer of Allergan Inc, expects tax reform to finally clear the decks for big industry consolidation.

  • Reuters12 days ago

    U.S. pharma executives expect deals to pick up after tax overhaul

    The Trump administration's tax overhaul should accelerate major acquisitions by drugmakers in 2018 after a slow year for deals in 2017, according to senior executives from some of the largest pharmaceutical manufacturers. The $1.5-trillion bill, which U.S. President Donald Trump signed into law in December, lowers the income tax rate for U.S. companies to 21 percent from 35 percent, encourages them to repatriate cash, and modifies numerous deductions. Brent Saunders, chief executive officer of Allergan Inc (AGN.N), expects tax reform to finally clear the decks for big industry consolidation.

  • See what the IHS Markit Score report has to say about Horizon Pharma PLC.
    Markit12 days ago

    See what the IHS Markit Score report has to say about Horizon Pharma PLC.

    Short interest is low for HZNP with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding HZNP totaled $3.37 billion.

  • What Does Horizon Pharma Public Limited Company’s (NASDAQ:HZNP) Share Price Indicate?
    Simply Wall St.13 days ago

    What Does Horizon Pharma Public Limited Company’s (NASDAQ:HZNP) Share Price Indicate?

    Horizon Pharma Public Limited Company (NASDAQ:HZNP), a pharmaceuticals company based in Ireland, saw a decent share price growth in the teens level on the NasdaqGS over the last few months.Read More...

  • Market Realist17 days ago

    How Analysts Rated Jazz Pharmaceuticals in December

    In December 2017, Jazz Pharmaceuticals (JAZZ) submitted a New Drug Application (or NDA) to the FDA for the approval of JZP-110.

  • See what the IHS Markit Score report has to say about Horizon Pharma PLC.
    Markit19 days ago

    See what the IHS Markit Score report has to say about Horizon Pharma PLC.

    Short interest is low for HZNP with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • 3 Top Value Stocks to Buy in 2018
    Motley Fool21 days ago

    3 Top Value Stocks to Buy in 2018

    Express Scripts Holding Company, Horizon Pharma plc, and Sanofi plc are three cheap stocks worth considering in 2018.

  • Horizon Pharma Gets FDA Nod for Procysbi Label Expansion
    Zacks24 days ago

    Horizon Pharma Gets FDA Nod for Procysbi Label Expansion

    The FDA approves label expansion for Horizon Pharma's (HZNP) Procysbi (cysteamine bitartrate) delayed-release capsules for children aged a year and older with nephropathic cystinosis.

  • Capital Cube25 days ago

    ETFs with exposure to Horizon Pharma Plc : December 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Horizon Pharma Plc Here are 5 ETFs with the largest exposure to HZNP-US. Comparing the performance and risk of Horizon Pharma Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • MarketWatch25 days ago

    Horizon Pharma shares jump 3% premarket after FDA expands use of treatment for metabolic disorder

    Horizon Pharma Plc shares climbed more than 3% in premarket trade Wednesday, after the company said it has received U.S. Food and Drug Administration approval to expand the indication for its treatment ...

  • Horizon Pharma Shows Improved Relative Price Performance; Still Shy Of Benchmark
    Investor's Business Daily25 days ago

    Horizon Pharma Shows Improved Relative Price Performance; Still Shy Of Benchmark

    A Relative Strength Rating upgrade for Horizon Pharma shows improving technical performance. Will it continue?

  • Stocks With Rising Relative Price Strength: Horizon Pharma
    Investor's Business Dailylast month

    Stocks With Rising Relative Price Strength: Horizon Pharma

    Horizon Pharma sees its Relative Strength Rating move into the 80-plus level.

  • Horizon Pharma Earns RS Rating Upgrade
    Investor's Business Dailylast month

    Horizon Pharma Earns RS Rating Upgrade

    Horizon Pharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

  • Market Realistlast month

    Analysts’ Recommendations for BioMarin in December 2017

    In October 2017, the FDA granted BioMarin's valoctocogene roxaparvovec its Breakthrough Therapy Designation.

  • Capital Cube2 months ago

    ETFs with exposure to Horizon Pharma Plc : December 4, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Horizon Pharma Plc Here are 5 ETFs with the largest exposure to HZNP-US. Comparing the performance and risk of Horizon Pharma Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • See what the IHS Markit Score report has to say about Horizon Pharma PLC.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Horizon Pharma PLC.

    Short interest is low for HZNP with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $2.68 billion over the last one-month into ETFs that hold HZNP are not among the highest of the last year and have been slowing.

  • Capital Cube2 months ago

    ETFs with exposure to Horizon Pharma Plc : November 24, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Horizon Pharma Plc Here are 5 ETFs with the largest exposure to HZNP-US. Comparing the performance and risk of Horizon Pharma Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • See what the IHS Markit Score report has to say about Horizon Pharma PLC.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Horizon Pharma PLC.

    Short interest is low for HZNP with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, ETFs holding HZNP are favorable, with net inflows of $3.35 billion.

  • Capital Cube2 months ago

    ETFs with exposure to Horizon Pharma Plc : November 13, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Horizon Pharma Plc Here are 5 ETFs with the largest exposure to HZNP-US. Comparing the performance and risk of Horizon Pharma Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Horizon Pharma Plc :HZNP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 10, 2017
    Capital Cube2 months ago

    Horizon Pharma Plc :HZNP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 10, 2017

    Categories: Yahoo FinanceGet free summary analysis Horizon Pharma Plc reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Horizon Pharma Plc – Amgen Inc., Aralez Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd. Sponsored ADR, Radius Health Inc, Alder Biopharmaceuticals, Inc., Merck & Co., Inc. and Pfizer Inc. ... Read more (Read more...)

  • See what the IHS Markit Score report has to say about Horizon Pharma PLC.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Horizon Pharma PLC.

    Short interest is low for HZNP with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $2.84 billion over the last one-month into ETFs that hold HZNP are not among the highest of the last year and have been slowing.

  • Horizon Pharma Plc breached its 50 day moving average in a Bearish Manner : HZNP-US : November 10, 2017
    Capital Cube2 months ago

    Horizon Pharma Plc breached its 50 day moving average in a Bearish Manner : HZNP-US : November 10, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Horizon Pharma Plc. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of HZNP earnings conference call or presentation 6-Nov-17 1:00pm GMT

    Q3 2017 Horizon Pharma PLC Earnings Call

  • Horizon Pharma (HZNP) Tops Q3 Earnings & Sales, Ups View
    Zacks2 months ago

    Horizon Pharma (HZNP) Tops Q3 Earnings & Sales, Ups View

    Horizon Pharma (HZNP) Q3 results were driven by growth from the orphan and rheumatology business.

  • TheStreet.com2 months ago

    Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers

    The Dublin firm on Nov. 6 unveiled third-quarter numbers that topped analysts' estimates and raised its full-year net sales outlook and the lower end of its 2017 adjusted Ebitda guidance.